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Despite efforts to scale up prevention of
mother-to-child transmission (PMTCT) of
HIV, over 1,000 infants continue to be
infected daily, particularly in sub-Saharan
Africa [1]. Disease progression in infants is
much more rapid than in older children
and adults, with mortality exceeding 50%
by 2 years of age in the absence of
antiretroviral therapy (ART) [2]. Although
combination ART has been available
since 1997, diagnosis and treatment of
infants is much more challenging com-
pared to older children and adults (Box 1).
Furthermore, until recently there was little
evidence to guide treatment approaches in
infants and young children, with interna-
tional policymakers relying on data from
cohort studies and expert opinion to
inform guidelines. In the past 5 years,
results have emerged from several ran-
domized clinical trials of children with
HIV under 2 years of age (Table 1) [3–8];
a systematic review of these trials has just
been published [9]. Here, we consider the
implications of research findings for forth-
coming World Health Organization
(WHO) guidelines and, ultimately, for
policymakers, who will need to weigh
efficacy and feasibility of interventions in
their particular settings in low- and
middle-income countries (LMIC).
When Should Antiretroviral
Therapy Be Started in Young
Children?
Several small, observational studies
suggested a benefit to starting ART early
in infants with HIV [10–12], but given the
challenges of treatment at this age, togeth-
er with lack of robust evidence, WHO,
European, and United States treatment
guidelines differed in their recommenda-
tions until 2007, when the Children with
HIV Early Antiretroviral Therapy
(CHER) trial provided definitive evidence
of the need to start ART soon after birth
[8]. Asymptomatic, immunologically in-
tact infants with HIV recruited before 12
weeks of age were randomized to start
ART either immediately, or once clinical
or immunological recommended thresh-
olds were reached. Infants starting imme-
diate ART had a 4-fold reduction in
mortality and disease progression com-
pared to infants starting deferred ART
(Table 1).
Although the CHER trial was conduct-
ed in South Africa, it changed policy in all
settings, supported by observational data
from Europe and the US [10–12]. Interim
WHO guidance in 2008 recommended
early treatment for infants (children under
1 year) in LMIC; in WHO 2010 guide-
lines, this recommendation was further
extended to include all children under 2
years of age. This age extension was not
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based on new data, but on recognition
that, first, the risk of disease progression
and mortality remains high between 1 and
2 years of age; second, immunological
markers are poorly predictive for clinical
progression in young children; and, third,
ART initiation improves retention in care
[13].
Adoption of Early Treatment
and Barriers to Its
Implementation
Many countries were quick to adopt
this guidance, but there are considerable
barriers to implementation of early treat-
ment. In particular, early ART initiation
relies upon early infant diagnosis (EID) of
HIV infection. Ideally, a continuum of
care should connect PMTCT, EID, and
infant ART services, but in reality there
are frequently poor linkages within this
cascade and high drop-out rates at each
Summary Points
N Early initiation of antiretroviral therapy (ART) in infants with HIV leads to a 4-fold
reduction in mortality compared to deferred ART
N Young children starting a first-line ART regimen containing a non-nucleoside
reverse transcriptase inhibitor (nevirapine; NVP) have a 2-fold higher risk of
treatment failure than those who start a regimen containing a protease
inhibitor (lopinavir/ritonavir; LPV/r)
N Use of LPV/r in infants is challenging due to its expense, unpalatable
formulation, and potential long-term toxicity
N Better formulations of ART are urgently required for infants and young children
Table 1. Published randomized clinical trials evaluating treatment strategies in infants and young children with HIV.
Question Trial Details Main Results
When should antiretroviral therapy
be started in young children?
N CHER (South Africa) [8]: 377 asymptomatic HIV-infected
infants aged 6–12 weeks, with CD4$25%, were randomized
to 1) Immediate ART for 40 weeks; 2) Immediate ART for 96
weeks; 3) Deferred ART according to WHO criteria. First-line
ART regimen comprised ZDV, 3TC, LPV/r. Primary outcomes:
time to death or failure of first-line ART (defined as failure to
reach CD4$20% by week 24 of ART; decrease to CD4
,20% after week 24; progression to CDC severe stage
B or stage C clinical events; toxicity requiring .1 drug
substitution within the same class, a switch to a new class,
or permanent discontinuation of treatment).
N PEHSS (South Africa) [7]: 63 infants with HIV were enrolled
at birth to a pilot feasibility study of early ART strategies, with
randomization to: 1) Immediate ART for 1 year; 2) Immediate
ART for 12–18 months with up to 3 structured treatment
interruptions; 3) Deferred ART according to WHO criteria.
First-line ART regimen comprised ZDV, 3TC, NVP, and NFV,
with NVP discontinued once virological suppression
(VL,50 copies/mL) achieved. Primary outcome:
proportion of infants progressing to AIDS by 3 years
of age (not yet reported). Clinical, virological, and
immunological outcomes have been reported.
N After median follow-up of 40 weeks (IQR 24–58),
mortality was 16% in the deferred ART group vs 4% in
the early ART groups (p,0.001). Early ART was
associated with 76% reduction in mortality and 75%
reduction in disease progression. The DSMB
recommended early dissemination of these findings
and urgent evaluation of untreated infants in the
deferred group for possible initiation of ART.
N No significant difference in 12-month mortality
between immediate (12%) and deferred (5%) groups
(p=0.65). However, study not designed or powered
to address the question of when to start ART. Infants
randomized to immediate compared to deferred ART
had reduced morbidity (median 7 vs 12 illness
episodes; p= 0.003), but similar virological and
immunological response to ART.
Which antiretroviral therapy should
be started in young children?
P1060 (South Africa, Zimbabwe, Zambia, Malawi,
Uganda, Tanzania, India) [5,6]: Two parallel trials of
first-line treatment regimens in children below
3 years of age who qualified for ART by WHO criteria.
Children in cohort 1 (n=164) had previously been
exposed to sd-NVP; children in cohort 2 (n=288)
had not previously been exposed to sd-NVP. Children
were randomized to 1) ZDV, 3TC, NVP or 2) ZDV, 3TC,
LPV/r. Primary outcome: Treatment failure by 24
weeks, defined as permanent discontinuation of the
treatment regimen for any reason, including death,
toxic effects, and virological failure (confirmed viral
load ,1 log10 copies/mL below the study-entry level
at 12–24 weeks, or confirmed viral load .400
copies/mL at 24 weeks).
In cohort 1, more children in the NVP group than
the LPV/r-group reached the primary endpoint of
treatment failure at 24 weeks (39.6% vs 21.7%,
respectively; p= 0.02). Similar results were seen in
cohort 2 (40.1% vs 18.6%, for NVP vs LPV/r,
respectively; p,0.001). In meta-analysis, the hazard of
treatment failure was 2.01 (95% CI 1.47, 2.77) times
higher for children starting ART with an NVP-based
regimen compared to a LPV/r-based regimen, with
no heterogeneity across the two trials.
Can antiretroviral therapy be
switched in young children?
NEVEREST (South Africa) [3,4]: 323 children under 2
years of age, previously exposed to sd-NVP, started a
first-line ART regimen comprising d4T, 3TC, LPV/r. 195
infants who maintained viral load ,400 copies/mL
for $3 months were randomized to 1) continue LPV/r
or 2) change to NVP. Primary outcome: Viral load .50
copies/mL at 52 weeks. Safety endpoint: Confirmed
viral load .1,000 copies/mL.
Children changing to NVP, compared to those staying
on LPV/r, had a lower hazard of VL.50 copies/mL
(HR = 0.62, 95% CI 0.41, 0.92; p= 0.02), but a higher
hazard of confirmed VL.1,000 copies/mL (HR = 10.19,
95% CI 2.36, 43.94; p= 0.002). Longer follow-up to
156 weeks confirmed these findings.
ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; d4T, stavudine; CDC, Centers for Disease Control; DSMB, Data and Safety
Monitoring Board.
doi:10.1371/journal.pmed.1001273.t001
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step. Current guidelines [13] recommend
that EID is undertaken at 4–6 weeks of
age in infants born to mothers with HIV.
However, most women do not know their
HIV status, because of late or incomplete
antenatal care and suboptimal access to
HIV testing and PMTCT services [1].
Furthermore, HIV diagnosis in infants is
more complex than in older children and
adults, because it entails virological test-
ing, which remains expensive, labour-
intensive, and technically challenging
compared to serological testing. Adoption
of early treatment guidelines for young
children will therefore only have impact if
the entire PMTCT/infant care pathway
is strengthened. With increased antenatal
HIV testing and PMTCT ART coverage,
the vast majority of paediatric infections
could be prevented; however, even in this
situation, those infants who do become
infected will largely be born to women
with unknown HIV status. For example,
with 95% uptake of antenatal testing and
95% PMTCT ART coverage, there will
be 2- to 3-fold more infants with HIV
born to mothers with unknown HIV
status; this rises to 15- to 20-fold if
PMTCT ART coverage is only 50% [14].
Although early infant ART is cost-
saving compared to deferred ART
[15,16], the relative treatment cost per
child is higher than for adults because of
the current price of appropriate formula-
tions and the need for lifelong treatment.
Unfortunately, where there are competing
demands for limited funds and resources,
early treatment of infants with HIV is
often therefore seen as a high-burden
activity. Initiation of the youngest children
on ART has lagged unacceptably behind
that of older children and adults because
of the challenges of treatment at this age
(Box 1).
Which ART Should Be Started in
Young Children?
The choice of first-line ART regimen
for infants with HIV is frequently com-
plicated by prior exposure to non-nucle-
oside reverse transcriptase inhibitor
(NNRTI) drugs, commonly used in
PMTCT programs. A single point muta-
tion in the virus confers high-level resis-
tance to nevirapine (NVP), which is a
preferred first-line drug in young children
due to its cost, tolerability, inclusion in
fixed-dose combination (FDC) tablets,
and ease of administration. The only
viable alternative for infants and young
children in LMIC is to use lopinavir/
ritonavir (LPV/r), a protease inhibitor
(PI), in place of NVP. The P1060 trial,
undertaken in six African countries,
compared first-line NVP-based or LPV/
r-based ART in young children (,3 years
of age) who either had (cohort 1) or had
not (cohort 2) been exposed to sd-NVP
prophylaxis (Table 1) [5,6].
Results from cohort 1 were consistent
with prior observational data [17], with a
higher rate of principally virological
treatment failure among children starting
a NVP- compared to a LPV/r-based
regimen [5]. More surprisingly, children
in cohort 2, who had not been exposed to
sd-NVP as far as could reasonably be
ascertained, and were nearly a year older,
showed a similar difference in outcome
between first-line regimens [6]. The
reasons underlying this difference have
been debated, but remain unclear.
Should Guidelines on ART for
Infants and Young Children Be
Changed?
WHO guidelines were amended in
2010 following the P1060 cohort 1 results,
to recommend LPV/r-based first-line reg-
imens for children under 24 months with
previous exposure to NNRTIs for
PMTCT [13]. A NVP-based regimen
remains the recommended first-line regi-
men for infants and young children
without previous exposure to NNRTIs.
What should policymakers do in light of
new data from P1060 cohort 2? The
findings appear compelling: a 2-fold in-
creased risk of treatment failure if an
infant’s first-line regimen contains NVP,
rather than LPV/r, whether or not the
child has previously been exposed to NVP
for PMTCT. However, there are advan-
tages and disadvantages to changing
guidelines to recommend universal LPV/
r-based ART in young children, and the
issues discussed below need to be consid-
ered.
Does the Evidence Support a
Change in Policy?
The P1060 trial was a robust, timely,
and well-conducted study, in a field where
few randomized controlled trial data exist;
the results were highly significant with no
heterogeneity across the two cohorts.
However, treatment failure was a compos-
ite endpoint; there were very few deaths
and the difference between NNRTI and
PI arms was mostly driven by virological
failure and toxicity. The virological end-
point was also composite (Table 1) and
relatively short-term (24 weeks); might
longer follow-up have led to a different
result? Results from P1060 contrast with
longer-term data from other settings. Data
from a European/US trial (PENPACT-1),
which followed 266 children with HIV (of
whom 68 were ,3 years) randomized to
first-line PI- or NNRTI-based ART for
median 5 years [18], and data from an
observational cohort of 437 European
infants starting either PI- or NNRTI-
based ART [19] and followed for median
5.9 years, both showed no significant
difference in virological outcome between
PI and NNRTI groups. In fact, in the
European infant cohort, a four-drug
regimen that included NVP and 3 NRTI
drugs was associated with better virologi-
cal suppression and CD4 recovery than a
three-drug PI-based regimen [19]. How-
ever, findings from Europe and the US
cannot necessarily be extrapolated to
LMIC. The P1060 trial certainly recruited
the most relevant population to address
Box 1. Challenges in the Treatment of Infants and Young
Children with HIV
N Virological testing is required to ascertain HIV infection status
N Identification of infected infants is frequently delayed
N Disease progression is rapid, with mortality peaking in the first few months of
life
N No reliable markers to predict rapid disease progression
N Limited repertoire of antiretroviral drugs and drug formulations
N Liquid formulations expensive, unpalatable, and difficult to carry/store
N Pharmacokinetics variable, due to developing metabolic pathways
N Frequent adjustment in dosing is required due to rapid growth during infancy
N Need for strategic drug sequencing in the context of lifelong treatment
N Adherence is challenging, with reliance on caregivers to administer medication
N Risk of drug resistance due to high viral loads during infancy
N Potential long-term toxicity of treatment, as ART is started during a
developmentally sensitive period of early life
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the question of which first-line regimen to
use in LMIC and it is unlikely that another
trial will address this question. Random-
ized data from the ARROW trial (http://
www.arrowtrial.org; ISRCTN 24791884),
which closes this year, will help to inform
whether an initial four-drug ART regimen
is beneficial in young children.
What Is the Feasibility of Starting
Young Children on PI-Based
Regimens?
LPV/r, the only widely available PI, is
more challenging to use in infants than is
NVP. LPV/r is currently only available as
a bitter-tasting liquid, which requires a
cold chain for transport, or as a paediatric
heat-stable tablet that cannot be crushed
as it rapidly loses bioactivity [20]. LPV/r is
generally less well tolerated than NVP and
children tend to gain weight less well [3,5].
Recent reports have described cardiac
toxicity and transient adrenal dysfunction
in newborns [21,22]; however, the long-
term toxicity of LPV/r-based regimens in
children starting treatment very early is
poorly documented. Although NVP has
well described toxicity, characterized by
rash, Stevens Johnson syndrome, and/or
hepatotoxicity, permanent discontinuation
of treatment in infants and young children
due to side effects is uncommon [23].
LPV/r has the advantage of a higher
genetic barrier to resistance than NVP. In
the CHER trial, only 7/375 (2%) infants
starting first-line LPV/r-containing ART
switched to second-line regimens after
median 4.8 years of follow-up [15]. Use
of LPV/r may therefore obviate the need
for viral load monitoring, especially since
it is unclear which second-line regimen
could feasibly be used in LMIC following
treatment failure with LPV/r, as NNRTI-
based regimens would be unlikely to be
robust. Darunavir (another PI) retains
activity after failure of LPV/r, but requires
separate ritonavir boosting and has not
been evaluated in young children because
of animal toxicity data. Integrase inhibi-
tors or newer NNRTI drugs may be
suitable for second-line regimens in chil-
dren, but are not yet available.
What Would Be the Cost
Implications?
LPV/r-based regimens are approxi-
mately 3-fold more expensive than NVP-
based regimens (Clinton Healthcare Ac-
cess Initiative, unpublished data). This is a
major consideration in the current context
of limited resources and funding uncer-
tainty for ART programs. However, use of
a more expensive regimen can be cost-
effective and appropriate economic evalu-
ations should be undertaken. The OC-
TANE trial reported superior outcomes
among NVP-exposed women who subse-
quently initiated a PI-based regimen,
compared to an NNRTI-based regimen
[24]. Despite a 12-fold increase in cost of
an adult LPV/r regimen compared to a
NVP regimen, first-line LPV/r was shown
to be very cost-effective in women previ-
ously exposed to sd-NVP [25].
It appears intuitive that changing guide-
lines to recommend universal LPV/r-
based ART would increase the number
of children starting LPV/r. However, in
light of the current drive to eliminate new
HIV infections in children [26], an
increasing number of mothers and infants
will access PMTCT interventions, which
are primarily NNRTI-based. As PMTCT
coverage increases, those infants who do
become infected will be eligible to start
LPV/r as a result of prior NNRTI
exposure, and the additional proportion
of infants starting LPV/r due to a change
in guidelines will fall as PMTCT coverage
increases.
Treatment 2.0 and the Need for
Equity
The WHO-led ‘‘Treatment 2.0’’ strat-
egy was developed to improve the effi-
ciency and impact of HIV care and
treatment programs in LMIC [27]. Be-
cause health care workers in lower-level
facilities manage adults and children
together, there is a strong justification for
harmonization with adult treatment as
much as possible. In this context, universal
LPV/r-based first-line regimens may limit
the decentralization of paediatric services
that is critically needed to narrow the
treatment gap between adults and children
[1]. The roll-out of LPV/r-based first-line
regimens for infants in South Africa, while
logistically feasible in most areas, has
highlighted the challenges in ensuring
cold-chain delivery and establishing effec-
tive procurement and supply chains down
to primary care settings.
Better Antiretroviral Drugs Are
Needed for Infants and Young
Children
Children with HIV in LMIC are a
largely neglected population, particularly
in terms of access to suitable formulations
[28]. There is an urgent need to produce
formulations of current drugs that are
suitable for young children, particularly
FDC tablets that can be dispersed or
crushed and mixed with food or liquids
(Box 2). The most widely prescribed
NNRTI-based regimens are available as
FDCs; however, there are currently no PI-
based FDCs and, due to the formulation of
LPV/r, full FDC regimens are extremely
unlikely to be developed. Given the
findings of the P1060 trials, development
of better PI-based regimens is a high
priority. The CHAPAS-2 trial (ISRCTN
01946535) is evaluating the pharmacoki-
netics and acceptability of a new heat-
stable ‘‘sprinkle’’ formulation of LPV/r for
young children. If this trial demonstrates
acceptability and equivalence of sprinkles
to existing formulations, then LPV/r
would be much easier to use in young
children.
Alternative Approaches
An alternative approach to long-term PI
treatment, explored in the South African
NEVEREST trial (Table 1), is to start all
infants on LPV/r, and later substitute
NVP [3,4]. Children changing to NVP in
NEVEREST were more likely to maintain
an undetectable viral load (,50 copies/
mL) than those staying on LPV/r, perhaps
because of better adherence to the more
palatable NVP formulation. However,
children changing to NVP were also more
likely to have episodes of higher virological
failure (.1,000 copies/mL) if they did fail,
compared to those staying on LPV/r,
likely because NVP has a low genetic
barrier to resistance.
Would this strategy be practical for
infants in LMIC? Virological monitoring
before and after changing to NVP is not a
realistic approach because access to viral
load testing remains limited and costly. A
simplified approach, using a fixed duration
of LPV/r treatment in early infancy then
switching to NVP once adherence be-
comes more challenging beyond infancy, is
more practical to implement; however,
this strategy still requires better and more
affordable PI formulations to be feasible.
The current recommendation for uni-
versal, lifelong treatment may be difficult
to sustain in LMIC because of cost, long-
term toxicity, and eventual likelihood of
virological failure. An alternative ap-
proach would be to start early ART
during infancy, then stop therapy when
risk of disease progression is lower. In
CHER, around one-third of children who
received early ART for 2 years and then
stopped had no clinical or immunological
indication to restart ART by the end of
follow-up at around 5 years of age [15].
However, these children all started ART
very early with high CD4 counts, and in a
smaller Kenyan study in which infants
started ART later, interruption appeared
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much less feasible [29]. Nonetheless, there
is a rationale for further exploring this
approach in children, provided treatment
interruption can be sufficiently long to
deliver worthwhile reductions in toxicity
and cost, and there is capacity to closely
monitor children off ART.
Where to Next?
While elimination of childhood infec-
tion is the most important goal, it is
unclear what will be achievable by 2015
[26]. Treatment guidelines will be revised
for children with HIV in 2013; before
then, it will be important to critically
consider current and forthcoming data.
Young children are already the most high-
risk and neglected group affected by the
HIV epidemic; only 23% of children in
need of ART in LMIC were receiving
treatment in 2010 [1]. Recommendations
must therefore balance evidence with
feasibility, and policymakers must contin-
ue to advocate a pipeline of appropriate
paediatric antiretroviral drugs to enable
evidence to be put into practice.
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